In a small group of 10 people with Graves' disease who received radioactive iodine after failing medication, 1 person needed to increase their thyroid medication again at 6 months, showing that RAI doesn't always control the disease and sometimes it gets worse.
Claim Context
In patients with Graves' disease who failed anti-thyroid drug therapy, a fixed 10 mCi dose of radioactive iodine resulted in 10% requiring increased ATD doses at 6 months, indicating that a subset of patients may experience persistent or worsening hyperthyroidism despite RAI treatment.
“At 6 months... 10% experienced worsening hyperthyroidism... 60% decrease ATD doses, and 10% remaining increased dose.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled incidence of persistent or worsening hyperthyroidism requiring increased ATD doses after fixed-dose RAI (10–15 mCi) in Graves' disease patients who failed prior ATD therapy.
A systematic review and meta-analysis of prospective cohort studies and RCTs reporting the need for increased ATD doses after RAI in Graves' disease patients with prior ATD failure, including at least 2000 patients across 25+ studies, with standardized definitions of 'worsening hyperthyroidism'.
Whether fixed-dose RAI increases the risk of persistent hyperthyroidism requiring increased ATD compared to higher RAI doses or thyroidectomy.
A double-blind RCT of 200 adults with Graves' disease and prior ATD failure, randomized to 10 mCi RAI, 15 mCi RAI, or thyroidectomy, with primary outcome of increased ATD dose requirement at 6 months, controlling for baseline TRAb and thyroid volume.
The incidence of persistent hyperthyroidism requiring increased ATD doses after 10 mCi RAI in a real-world population of Graves' disease patients.
A prospective cohort study of 300 adults with Graves' disease and prior ATD failure, treated with fixed 10 mCi RAI, with serial TSH, FT4, and ATD dose adjustments recorded at 3, 6, 12, and 24 months, and baseline data on TRAb, thyroid volume, and smoking.
The prevalence of increased ATD use at a single time point after RAI in Graves' disease patients.
A cross-sectional survey of 400 adults with Graves' disease who received RAI at least 6 months prior, measuring current ATD dose and TSH/FT4 levels, and collecting retrospective treatment history.
Anecdotal reports of hyperthyroidism worsening after RAI in individual patients.
A case series of 10–20 patients with Graves' disease who required increased ATD doses after RAI, documenting TSH/FT4 trajectories, TRAb levels, and timing of dose changes.